Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antiepileptic drugs (AEDs) are known to associate with an increased risk of major congenital malformations (MCMs) in children born to women who become pregnant while taking them. As the indications for AEDs continue to diversify, novel AEDs emerge, and polytherapy becomes more prevalent, the volume and complexity of the information relating to teratogenic risk can become unmanageable for the clinician. This in turn makes accurate education of pregnant women treated with AEDs regarding the risk of MCMs challenging. To enable clinicians to provide better information regarding the potential teratogenic risk of AEDs, we outline here the method we have employed to underpin a new system of real‐time risk analysis, “EpiRisk.” When launched, EpiRisk will offer a user‐friendly, online clinical tool, compatible with all modern Internet browsers, smart phones, and personal computers. Using the most current published data, as well as “real world” data from the UK and the Australian Pregnancy Registers, EpiRisk will enable clinicians to quickly and accurately assess the teratogenic risk of AEDs in mono‐ and polytherapy. EpiRisk may thus provide a future‐proof central hub for empowering patients, clinicians, and registries by delivering evidence‐based information on the teratogenic risk of the AEDs in pregnant women with epilepsy through an easily accessible platform.

Original publication

DOI

10.1002/epi4.12109

Type

Journal article

Journal

Epilepsia Open

Publisher

Wiley

Publication Date

22/03/2018

Volume

2

Pages

281 - 285

Keywords

Antiepileptic drugs; App; Clinical tool; Epilepsy; Pregnancy; Teratogenicity